Skip to main content
OpenTrials
Completed

NCT Number: NCT04834934

Artificial Intelligence - SARS-CoV-2 (COVID-19) Risk Evaluation

The management of COVID-19 patients in overwhelmed hospital facing the pandemic is a clinical challenge.

The improvement of decision making may allow a better allocation of available resources and a better treatment of patients at higher risk.

Chest CT has been widely adopted for COVID-19 pneumonia diagnosis. Several experiences documented the capability of Artificial Intelligence to improve and fasten COVID-19 pneumonia detection, mainly using chest X-ray.

Aim of the present study was to develop and validate an Artificial Intelligence approach integrating clinical and imaging data (automatically extracted through the adoption of dedicated neural networks) for the creation of a cloud platform capable of performing automatic patients risk stratification. Such an approach could be used for triage of COVID-19 patients in the emergency department, with the aim to improve healthcare personnel decision-making and allocation of resources during health emergencies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS San Raffaele

Milan, 20132, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • confirmed SARS-CoV-2 infection with RT-PCR
  • non contrast chest CT scan performed within 72 hours after admission to the emergency department

Exclusion criteria

  • age < 18 ys

Treatment and study plan

Primary outcomes

  1. Training, testing and validation of an AI platform for predicting Italian first wave Covid-19 patients prognosis.

    Time frame: 9 months

Secondary outcomes

  1. Validation of the developed AI platform on italian second wave of Covid-19 patients

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele

Other

Collaborators

  • ASST Bergamo Est
  • Centro Cardiologico Monzino
  • Microsoft Corporation
  • NVIDIA Corporation
  • Orobix Srl
  • PORINI Srl
  • Regione Lombardia

Registry information

Official study title

Artificial Intelligence - SARS-CoV-2 Risk Evaluation

Acronym: AI-SCoRE

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Apr 8, 2021
Registry last updated
May 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.